| Schedule of Seminars, November 14,2005 SVOD participants will have a chance to attend seminars taught by the Stanford Graduate School of Business professors, Silicon Valleyventure capitalists, and high level business professionals. Participants will be offered an opportunity to develop their own schedule of seminars based on their personal interests and educational needs. Seminars are open only to the registered participants.
Several seminars will be offered at certain time slots. To facilitate the choice of seminars by participants, each seminar is assigned a track according to the audience to which it is recommended:
ENT - general entrepreneurship
VC - venture capital
ACAD - commercialization of academic science
BIO - life sciences
BD - business development
Seminars are only offered on November 14.
Seminars are subject to change at any time without notice. | | | Track | | 9:00 AM-10:30 AM Main Hall | ENTREPRENEURSHIP: FOUNDING AND FUNDING A NEW VENTURE Charles A. Holloway [1]
Kleiner Perkins Caufield and Byers Professor of Management, Graduate School of Business, Stanford University Max Levchin [2]
Founder and CEO, Slide; co-founder and former CTO, PayPal John Malloy [3]
Managing General Partner, BlueRun Ventures Venture funding is one of many ways available to an entrepreneur to finance a growing company. Would your company benefit from venture financing? The session will cover the following topics:
• Start-up: financing strategies
• Pros and cons of getting funded by a venture capital firm
• What venture capitalists are bringing to the table
• When and how to approach venture capitalists | ENT | | 10:30 AM-11:30 AM Main Hall | VALUATION AND FINANCING FOR ENTREPRENEURS: A ONE-HOUR CRASH COURSE Ilya A. Strebulaev [4]
Assistant Professor of Finance, Graduate School of Business , Stanford University • How to come up with an estimation of the value of your project/firm? • How to finance your idea to make it into a successful project into a successful company? • How to write financial contracts with your money providers? • How to optimize your exit strategy? | ENT |
Room Q2 | VENTURE CAPITAL BUSINESS MODEL; STRUCTURE OF A VENTURE FUND Alexei Andreev [5]
Managing Director and Executive Vice President, Harris & Harris Group How do venture capitalists make money? What creates an incentive for them to build successful businesses? This session will cover the basis of venture capital business models in the United States :
• Legal and financial structure of a venture capital fund: Limited and General Partners
• Financial mechanisms of venture capital: capital commitment, capital call, carried interest | VC |
Room Q1 | PATH TO MONEY AND MARKETSHARE: AN INTRODUCTION TO TECHNOLOGY LICENSING AND OPEN SOURCE LICENSING Chris Nadan [6]
Associate General Counsel and Director for Sun Microsystems, Inc.
Most of the product development and marketing in technology business are capital intensive programs. In many cases the company doesn't have sufficient resources to develop or market its product in house. Is out-licensing the intellectual property to big players in the field the best solution in this case? The seminar will discuss:
• Types and terms of licensing agreements
• Strategic decisions and negotiating a licensing deal | BD | | 11:30 AM-12:30 PM Main Hall | VENTURE CAPITAL VALUE ADDED: WHAT VENTURE CAPITALIST BRINGS TO THE TABLE Franklin "Pitch" Johnson [7]
Founding Partner, Asset Management Company
Venture capitalists invest much more than just cash in their portfolio companies: they invest their time, experience, and network to help entrepreneurs build their ventures. This session will discuss:
• Finding the right venture investor
• Venture capital value added: what to expect from a venture capitalist
• Venture capitalist as your Board member | ENT |
Room Q1 | VENTURE INVESTING IN LIFE SCIENCES Dr. Albert Cha [8]
Managing Partner, Vivo Ventures
Funding a biomedical startup is quite different from funding a technology company. There is a set of milestones determined primarily by the regulatory process of a medical product approval in the United States . These milestones drive all aspects of venture funding and the valuation of the company. The seminar will discuss:
• Finding the right venture capitalist for your life sciences company
• Venture capital process in Life Sciences
• Fundable milestones and valuation
• Product development and exit strategies | BIO | | 1:00 PM-2:00 PM Main Hall | STRUCTURING A VENTURE CAPITAL DEAL Kirk Dunn [9]
CEO, PowerFile
Once you know that your company will benefit from venture money, you have made your pitch and got the interest – what is the next step? How to lay a ground for the long-term successful relationship? The session will focus on the following topics:
• Specific due diligence terms you need to be aware of
• Essentials of the legal terms of financing
• Valuation and fundable milestones
• How to create a win-win term sheet?
• Exit Strategies: three practical ways | ENT |
Room Q1 | DEVELOPING SUCCESSFUL BIOMEDICAL PRODUCT Barry M. Sherman [10]
Executive Vice President, Development, BiPar Sciences, Inc.
The session will focus on the product development process of drugs and medical devices in the United States . Discussion topics include:
• Fundamentals of biotech product positioning
• FDA process and product development
• Marketing and sales of a new product line in the United States
• Building successful corporate relationships | BIO |
Room Q2 | IP STRATEGIES FOR START-UPS Daniel L. Appleman [11]
Partner, Heller, Ehrman, White, & McAuliffe
The session will cover the essentials of startup intellectual property issues:
• How to leverage intellectual property as a strategic asset to build a successful company
• Intellectual property protection
• Technology transfer | ENT | | 2:00 PM-3:00 PM Main Hall | GETTING READY FOR A PRODUCT LAUNCH Dave Girouard [12]
General Manager, Google Enterprise
The session will focus on the issues related to successful launch of the high technology product in the US market. Discussion topics:
• How to position yourself for success: market assessment and competitive analysis to define value proposition
• How to plan the launch: coordinating R&D, product management and marketing efforts.
• Creating the buzz: communicating your value proposition to the customers, partners and press. | ENT |
Room Q1 | ESTABLISHING CORPORATE PRESENCE IN US Leo Ryzhenko
President, US Business Services
This session will cover essentials of startup organization and building a growing enterprise: specifics of US legal, accounting and taxation issues, as well as marketing and professional services entrepreneurs need to be aware of. The seminar will cover such practical issues as:
• Setting up an office in the United States
• Legal aspects of starting business in US
• Finding and using vendors and professional services
• What not to do | ENT | | 3:00 PM-4:00 PM Room Q1 | BUILDING A BUSINESS TEAM Alec Miloslavsky [13]
Head of Product Development and Strategy & Co-Founder, Exigen Group, Inc.
Finding managerial and business talent in the United States is the largest challenge that an entrepreneur from another country may face. Where to find the best CEO? Why are those sales people so expensive? The seminar will cover the following topics:
• US management team: the key success factor
• Building your first Board of Directors and Scientific Advisory Board
• Leveraging your relationships with venture capitalists
• Headhunters: pros and cons | ENT |
Main Hall | START-UP EXIT STRATEGIES Gary Benton [14]
Partner, Pillsbury Winthrop Shaw Pittman LLP
Byron Deeter [15]
Venture Partner, Bessemer Venture Partners
The venture capitalist starts thinking about exiting the deal when he makes the investment. The seminar will discuss which exit strategies are available for the venture capitalist and their advantages:
• IPO: windows of opportunity
• Mergers and Acquisitions
• The role of financial intermediaries
• Exit valuations | VC |
Room Q2 | LICENSING A BIOMEDICAL PRODUCT AND DEVELOPING SUCCESFUL CORPORATE RELATIONSHIPS Brad W. Crawford [16]
Director Licensing, Amgen, Inc. Licensing is a viable option for many biotech companies that don't have substantial resources for product development • How to approach licensing partners in the US • Licensing terms and conditions • Win-win licensing deals | BIO | | 4:00 PM-5:00 PM Room Q1 | VENTURE CAPITAL PROCESS: WHAT INVESTORS LOOK FOR Peter Loukianoff [17]
Partner, Alloy Ventures
Raising money is not an easy process. How do you package your company to be an attractive venture investment target? The seminar will discuss the following topics:
• Key success factors in fundraising
• Executive summary and its role in the process
• What is a successful pitch?
• Writing a business plan: some of the best recipes | ENT |
Main Hall | BUILDING A SUCCESSFUL VENTURE PORTFOLIO Steve Jurvetson [18]
Managing Director, Draper Fisher Jurvetson
What makes a successful venture capital firm? This seminar will cover the aspects of venture capital process from an investor’s perspective and strategies of building and managing a successful venture portfolio:
• Due diligence process
• Leading vs. following
• Building syndicates
• Helping the companies to grow and exit
• Managing a portfolio of private companies | VC | There will be Special Programs for US Venture Capital Investors (marked USVC) and representatives of the Russian academic science and technology parks (marked ACAD) on November 15: | | | Track | | 10:00 AM-11:00 AM | OFFICE OF TECHNOLOGY LICENSING: COMMERCIALIZING ACADEMIC SCIENCE Katharine Ku
Director, Office of Technology Licensing, Stanford University Representatives of the Stanford Office of Technology Licensing will share their experiences with representatives of the Russian Academic sector and entrepreneurs. The following topics will be covered:
• How to protect the interests of both the entrepreneur and the university
• Typical licensing terms, cash and royalties vs. equity
• Stanford experience: success stories | ACAD | | 10:00 AM-11:00 AM
Room Q2 | Russian Technologies: Opportunities for Venture Capital Investment Joseph Bowman [19]
Senior Investment Manager, Russian Technologies In spite the fact the Russia has traditionally had a large pool of highly qualified scientists and engineers, venture capital industry in the country is still in its infancy. Many private equity firms has been moving to Russia recently; however, most of them invest in infrastucture and businesses related to natural resources. Traditional venture capital is scares in the country. The seminar will cover the environment in Russia for growing technology companies, obstacles venture capitalists deal with, and investment opportunities in the Russian technology sector that have a potential to reach the global market. | USVC | | 12:00 PM-2:00 PM | LUNCH WITH STANFORD FACULTY | ACAD | | 2:20 PM-3:20 PM
Room Q2 | Ukraine: New Frontiers for Venture Capital Roman Kyzyk [20]
Managing Partner, DFJ Nexus Serhiy Loboyko [21]
Managing Partner, DFJ Nexus Juha Christensen [22]
Ex-vice president of Microsoft, President of Sonopia Inc. Vladimir Bilodid [23]
CEO, United Software Corporation Ukraine is relatively new to the concept of venture capital.
However, the country's skilled, low cost technologists and West-leaning president make it a likely area for investment. Menlo Park based venture capital firm DFJ is forming a new fund, DFJ Nexus, aimed at Ukraine. The seminar will discuss the investment climate and potential investment opportunities in the country. | USVC | | 3:00 PM-4:00 PM | MEETING WITH REPRESENTATIVES OF BASES COMPETITION
The Business Association of Stanford Engineering Students organizes an annual business plan competition in which students from all Stanford departments interact and participate. Representatives of BASES will share their experience and the role of the project in helping accelerate entrepreneurial access to capital and managerial talent. | ACAD |
|
